Recombinant VEGFA (Brolucizumab Biosimilar) antibody

Catalog No. ABIN7795130

This Mouse Monoclonal antibody specifically detects VEGFA (Brolucizumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.

Quick Overview for Recombinant VEGFA (Brolucizumab Biosimilar) antibody (ABIN7795130)

Target: VEGFA (Brolucizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-VEGFA (Brolucizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody

Characteristics: Brolucizumab Biosimilar uses the same protein sequences as the therapeutic antibody brolucizumab. Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human VEGF-A

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for VEGFA (Brolucizumab Biosimilar)

Target: VEGFA (Brolucizumab Biosimilar)

Alternative Name: Brolucizumab Biosimilar

Target Type: Biosimilar